Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2203 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Risdiplam		
Initial application — spinal muscular atrophy (SMA) Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites (tick boxes where appropriate) Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation Patient is 18 years of age or under Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age Patient is pre-symptomatic and Patient has three or less copies of SMN2		
Renewal — spinal muscular atrophy (SMA) Current approval Number (if known):		
There has been demonstrated maintenance of motor milestone function since treatment initiation Patient does not require invasive permanent ventilation (at least 16 hours per day) in the absence of a potentially reversible cause while being treated with risdiplam Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy		

I confirm the above details are correct and that in signing this form I understand I may be audited.